A recent study, published in Clinical Genitourinary Cancer, looked at the clinical features, treatment outcomes and genetic profiles of patients with mucinous tubular and spindle-cell carcinoma (MTSCC), a rare type of kidney cancer.
There were 25 patients in the study, most of which had asymptomatic low-grade and localised tumours. Six patients had metastatic disease. The 3-year overall survival rate was 84.8% for all 25 patients, and 5 patients had clinical features that suggested high-grade tumours associated with metastatic disease.
The study concluded that mucinous tubular and spindle-cell carcinoma is a low-grade disease with generally favourable outcomes. However, worse outcomes are associated with high-grade clinical features. These patients should be referred to centres of excellence for genomic testing.